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Objective: Acute kidney injury (AKI) is a sequela of sepsis associated with increased morbidity and mortality. We
sought to determine if individuals with elevated baseline levels of inflammation and endothelial cell activation are
at increased risk for future AKI after sepsis.
Methods: We conducted an analysis of individuals developing sepsis in the national 30,239 subject REGARDS
cohort. Biomarkers measured at the beginning of an 8-year observation period included high-sensitivity C-reactive
protein (hsCRP), interleukin-6 (IL-6), tumor necrosis factor (TNF-α), E-selectin, inter-cellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and urinary Albumin-to-creatinine ratio (ACR). We defined
subsequent sepsis as hospitalization for a serious infection with ≥2 Systemic Inflammatory Response Syndrome
(SIRS) criteria. We excluded patients with prior dialysis or kidney transplantation, or those receiving less than two
serum creatinine (sCr) measurements during hospitalization. We defined AKI as an increase in sCr ≥0.3 mg/dL from
the initial sCr measurement, or the initiation of hemodialysis. Using logistic regression, we evaluated the associations
between AKI and biomarker quartiles, adjusting for comorbidities.
Results: We identified 212 sepsis cases encompassing 41 (19.3%) AKI. Elapsed time from biomarker measurement
to sepsis episode was 3.1 years (IQR 1.6-4.5). Compared with non-AKI, AKI individuals exhibited higher TNF-α (9.4 vs.
6.2 pg/mL, p = 0.003) and ACR (504.82 vs 61.81 mg/g, p < 0.001). hsCRP, IL-6, E-selectin, ICAM-1 and VCAM-1 were
similar between AKI and non-AKI. After adjustment for confounders, AKI after sepsis was more likely in those with
higher E-selectin (adjusted ORs 2.91 (0.95-8.93), 1.99 (0.61-6.47), 4.01 (1.30-12.35), test of linear trend p = 0.04), and
higher ACR (adjusted ORs 2.29 (0.99-5.30), 10.67 (3.46-32.90), test of linear trend p < 0.001). Baseline hsCRP, TNF-α,
IL-6, VCAM-1 and ICAM-1 were not associated with AKI after sepsis.
Conclusion: Elevated baseline levels of E-selectin and ACR are associated with future AKI in the setting of sepsis.
Baseline inflammatory and endothelial activation biomarkers may be useful for predicting future risk of AKI in sepsis.
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Acute Kidney Injury (AKI) is the syndrome of rapid loss
of kidney function, a process that may result from de-
creased renal blood flow, obstruction of the outflow
tract, or damage to the renal filtration system (KDIGO
Clinical Practice Guideline for Acute Kidney Injury. Sec-
tion 2: AKI Definition 2012). AKI affects over 600,000* Correspondence: hwang@uabmc.edu
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in any medium, provided the original work is ppatients annually and is associated with over 120,000
deaths (Hoste and Kellum 2006). Sepsis, the syndrome
of microbial infection complicated by systemic inflam-
mation, is associated with an estimated 750,000 hospital
admissions, 570,000 Emergency Department visits,
200,000 deaths and $16.7 billion in medical expenditures
annually in the United States (Angus et al. 2001; Wang
et al. 2007). While potentially resulting from shock, sur-
gery and toxic drugs, AKI often ensues following sepsis
(Waikar et al. 2008; Bagshaw et al. 2010).n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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lying sepsis, inflammation and endothelial activation play
prominent roles (Aird 2003; Kellum et al. 2007; Aird
2007). For example, in a cohort of 1,886 subjects hospita-
lized for community-acquired pneumonia, Kellum, et al.
observed that inflammatory cytokines (interleukin-6,
interleukin-10, tumor necrosis factor-α) were higher in in-
dividuals that developed severe sepsis or septic shock
(Kellum et al. 2007). Recent attention has focused on the
role of endothelial activation and dysfunction in sepsis
pathophysiology (Aird 2003, 2007; Shapiro et al. 2010). In
a prior study we found that individuals with high circula-
ting levels of inflammatory and endothelial cell activation
biomarkers were prone to future episodes of sepsis (Wang
et al. 2013b).
While ample data describe the characteristics of indi-
viduals suffering from AKI, there are currently few
methods for identifying the individuals at highest future
risk for developing AKI. With knowledge of an individ-
ual’s risk for developing AKI, it may be possible to initi-
ate treatment at the earliest stages of illness or to
introduce measures to prevent AKI. As in sepsis, inflam-
mation and endothelial cell activation are prominent fea-
tures of AKI pathophysiology. Markers of inflammation
and endothelial activation have been associated with
AKI in both in vitro and in vivo investigations, especially
in the setting of sepsis (Wan et al. 2003; Wan et al.
2008). In this preliminary study, we sought to evaluate
the association between such markers of inflammation
and endothelial activation at baseline and the risk of fu-
ture AKI after sepsis.
Results
Of 300 sepsis hospitalizations, we excluded 85 participants
with a history of kidney transplant (n = 8), a history of
end-stage renal disease (n = 5), or who received less than two
serum sCr measurements during hospitalization (n = 79).
Of the remaining 215 cases of sepsis, 41 (19.1%) met cri-
teria for AKI. Elapsed time from biomarker measurement
to sepsis episode was 3.1 years (IQR 1.6-4.5). Elapsed
times to the sepsis event were similar between AKI (me-
dian 2.8 years, IQR: 1.0-4.7) and non-AKI (3.3 years, IQR
1.6-4.5) cases (Wilcoxon rank-sum p = 0.94).
Participants with AKI were more likely to have a history
of hypertension, 92% vs 74%; p = 0.03 (Table 1). Among
the 41 patients with AKI, most AKI developed within two
hospital days (Table 2). All other baseline characteristics
were similar between the participant groups. Baseline
levels of TNF-α and urine albumin-to-creatinine ratio
(ACR) were higher in individuals who developed septic
AKI (Table 3).
After adjusting for hypertension and baseline eGFR,
the highest quartile of E-selectin was associated with
AKI (OR 4.01; 95% CI: 1.27-12.69). (Table 4) We observeda statistically significant linear trend between E-selectin
quartiles and the odds ratios for AKI (p = 0.045). The
highest tertile of ACR was also associated with the devel-
opment of sepsis (OR 10.67; 95% CI: 3.46-32.90). We ob-
served a linear trend between ACR tertiles and odds ratios
for AKI (p < 0.001). Baseline CRP, TNF-α, IL-6, VCAM
and ICAM were not associated with AKI after sepsis.
Discussion
Previous studies indicate that biomarkers of inflammation
and endothelial cell activation are increased in sepsis, and
that sepsis is a major cause of Acute Kidney Injury (AKI)
(Chertow et al. 2005; Hoste and Kellum 2006; Angus et al.
2001; Aird 2007). In this preliminary study, we observed
associations between baseline biomarkers E-Selectin and
urine albumin-to-creatinine ratio (ACR) and the risk of
future AKI after sepsis. This association persisted after ad-
justment for potential confounders. Our observations sup-
port the hypothesis that before overt renal cellular injury
has occurred, there may be alterations in microcirculation
and tissue oxygenation that predispose individuals to renal
damage (Okusa et al. 2013). This concept is especially
relevant to the septic state, where inflammation and endo-
thelial cell activation are prominent (Cheng et al. 2012).
There are plausible connections between inflammation
and endothelial cell activation and acute kidney injury.
TNF-α is an inflammatory marker released by activated
macrophages, monocytes and neutrophils and has been
shown to have a major role in both sepsis and septic
AKI (Aird 2007; Wolfs et al. 2002; Xu et al. 2013; Wan
et al. 2003). Renal endothelial cells are activated by TNF-
α, further perpetuating the pro-inflammatory state and
potentially sensitizing kidney tissue to subsequent damage
(Aird 2007; Wolfs et al. 2002). Acute endothelial cell
changes may lead to altered vascular reactivity, permeabil-
ity, adherence of leukocytes, coagulation and microvascu-
lar vasomotor autoregulation, perpetuating AKI.
Various studies have shown albuminuria to be a result
of endothelial activation, capillary permeability, and sys-
temic inflammation in both the baseline and septic states
(Zhang et al. 2012). Albuminuria is established as an in-
dicator of kidney function in the general population and
has been shown to predict AKI, length of stay, and
mortality in the acute care setting (Zhang et al. 2012;
Gansevoort et al. 2011). However, our approach is novel
as there have been no evaluations of the association of
baseline ACR measured prior to hospitalization for sep-
sis with risk of future AKI development.
The novelty of our study is that the indicators of ab-
normal inflammatory and endothelial cell response were
detected at baseline, prior to the onset of sepsis and
resulting AKI. These observations highlight the potential
use of baseline biomarker profiles to identify individuals
at risk of developing AKI, setting the stage for mitigating
Table 1 Characteristics of participants hospitalized for sepsis
Characteristic AKI No AKI p-value*
(n = 41) (n = 174)
Age
<50 1 (2.4%) 0 (0.0%) 0.21
50–59 3 (7.3%) 26 (14.9%)
60–69 14 (34.0%) 59 (33.9%)
70–79 16 (39.0%) 59 (33.9%)
≥ 80 7 (17.0%) 30 (17.2%)
Sex
Male 20 (49.0%) 89 (51.2%) 0.79
Female 21 (51.2%) 85 (48.9%)
Race
Black 15 (37.0%) 42 (24.1%) 0.10
White 26 (63.0%) 132 (75.9%)
Income
<$20 k 14 (34.0%) 39 (22.4%) 0.29
$20-34 k 12 (29.0%) 46 (26.4%)
$35-74 k 10 (24.0%) 53 (30.5%)
≥$75 k 1 (2.4%) 19 (10.9%)
Refused 4 (9.8%) 17 (9.8%)
Education
Less than High School 8 (20.0%) 31 (17.8%) 0.10
High School Grad 10 (24.0%) 40 (23.0%)
Some College 12 (29.0%) 57 (32.8%)
College Grad 11 (27.0%) 46 (26.4%)
Smoking
Never 15 (37.0%) 53 (30.5%) 0.50
Past 17 (42.0%) 90 (51.7%)
Current 9 (22.0%) 31 (17.8%)
Alcohol
None 23 (56.0%) 110 (63.2%) 0.33
Moderate 15 (37.0%) 54 (31.0%)
Heavy 1 (2.4%) 8 (4.6%)
Missing 2 (4.9%) 2 (1.2%)
Hypertension
No 3 (7.3%) 45 (25.9%) 0.03
Yes 38 (93.7%) 128 (73.6%)
Missing 0 (0.0%) 1 (0.6%)
Coronary Heart Disease
No 26 (63.0%) 114 (65.5%) 0.74
Yes 15 (37.0%) 58 (33.3%)
Missing 0 (0.0%) 2 (1.2%)
Diabetes
No 23 (56.0%) 116 (66.7%) 0.20
Yes 18 (44.0%) 58 (33.3%)
Table 1 Characteristics of participants hospitalized for sepsis
(Continued)
Hyperlipidemia
No 15 (37.0%) 48 (27.6%) 0.39
Yes 26 (63.0%) 123 (70.7%)




≥90 mL/min per 1.73 m2 8 (19.5%) 45 (25.9%) 0.01
60–89.9 13 (31.7%) 84 (48.3%)
45–59.9 7 (17.1%) 25 (14.4%)
<45 13 (31.7%) 19 (10.9%)
Missing 0 (0.01%) 1 (0.6%)
Excludes individuals with a prior history of kidney transplant or end-stage
renal disease, or individuals receiving only one creatinine measurement during
hospitalization. *By Chi-square test. AKI = acute kidney injury.
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in murine models, Coldeway et al. and Choi et al. among
others have demonstrated the use of erythropoietin and
glucocorticoids as prophylaxis for AKI in sepsis (Choi
et al. 2013; Coldewey et al. 2013). While not used in
current clinical practice, the identification of individuals
at risk for future AKI has tremendous implications for
care. This information could guide clinicians in the care
of individuals at heightened risk for AKI; for example,
selecting renal-sparing medications, avoiding of radiologic
contrast, or implementing of renal-protective strategies
early in the course of hospitalization. We emphasize that
these biomarkers were measured at healthy baseline prior
to illness – not after the onset of sepsis. Further investiga-
tion of inflammatory markers in disease progression is
warranted given the robust opportunities for illness pre-
vention and outcomes improvement.Table 2 Characteristics of creatinine measurements
among participants hospitalized with sepsis
Characteristic AKI No AKI
(n = 41) (n = 174)
Initial creatinine (mg/dL – median, IQR) 1.8 (1.3-2.8) 1.2 (0.9-1.7)
Maximum creatinine (median, IQR) 2.6 (1.9-4.0) 1.3 (1.0-1.7)
Maximum rise in creatinine from
index creatinine (median, IQR)
0.6 (0.4-1.0) 0.0 (0.0-0.1)
Number of measurements to
maximum creatinine
(median, IQR)
3.0 (2.0-4.0) 1.0 (1.0-2.0)
Elapsed days to maximum creatinine
(median, IQR)
1.8 (0.6-2.8) 0.0 (0.0-0.6)
Excludes individuals with a prior history of kidney transplant or end-stage
renal disease, or individuals receiving <2 creatinine measurement during
hospitalization. AKI = acute kidney injury.
Table 3 Baseline biomarkers and acute kidney injury (AKI) after hospitalization for sepsis
Biomarker AKI No AKI p-value*
Median (IQR) Median (IQR)
(n = 41) (n = 174)
C-Reactive Protein (mg/dL) 3.23 (1.55-8.60) 3.27 (1.75-6.17) 0.91
TNF-Alpha (pg/mL) 5.22 (4.15-7.76) 7.04 (4.94-9.74) 0.009
IL-6 (pg/mL) 3.48 (2.28-5.60) 3.81 (2.73-6.12) 0.19
E-selectin (ng/mL) 46.15 (33.36-60.17) 49.03 (36.93-66.90) 0.11
VCAM (ng/mL) 1171.17 (1005.17-1343.42) 1186.91 (1055.58-1429.28) 0.38
ICAM (ng/mL) 150.80 (125.50-189.63) 151.10 (117.22-194.74) 1.00
Urine Albumin-to-Creatinine Ratio (mg/g) 9.09 (5.88-24.39) 38.57 (9.57-313.39) <0.001
*Comparison by Wilcoxon Rank-Sum test.
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and endothelial cell activation, other studies have identi-
fied markers associated with early active AKI. For ex-
ample, elevated serum and urine levels of Neutrophil
Gelatinase-Associated Lipocalin (NGAL), a glycoprotein
produced by epithelial tissues throughout the body, have
been associated with AKI in the setting of sepsis
(Ostermann et al. 2012; Bagshaw et al. 2010; Martensson
et al. 2010). Kidney Injury Molecule-1, a transmembrane
glycoprotein produced by damaged proximal tubular cells
is a marker of early AKI (Ostermann et al. 2012; Han
et al. 2008; Liangos et al. 2009). Interleukin-18, a pro-
inflammatory cytokine released from injured proximal
tubule cells, has been used in conjunction with glom-
erular filtration rate diagnose or predict progression of
AKI (Liangos et al. 2009; Endre et al. 2011). Other markers
of AKI include Cystatin C and Liver-type Fatty-acid Bind-
ing Protein. (Ostermann et al. 2012; Herget-Rosenthal
et al. 2004; Iannitti et al. 2011). Additional study must
identify if these markers can be used to predict the
future risk of AKI.Limitations
We studied a narrow selection of biomarkers and in-
cluded a portion of the full REGARDS cohort. We did
not consider other potentially relevant biomarkers such
as interleukin-10, soluble fms-like tyrosine kinase-1
(sFlt-1), plasminogen activator inhibitor-1 (PAI-1) or
NGAL. An ideal study would encompass examination of
a broader range of baseline biomarkers involving all sub-
jects in the cohort. However, our preliminary study lays
the foundation for a more comprehensive examination
of a broader range of biomarkers and mechanisms. Our
study examined only a single measurement of each bio-
marker at the beginning of the REGARDS study. Repeat
blood and serum samples are not yet available for
REGARDS participants, although a repeat examination
of subjects in the cohort is in progress.We included only individuals receiving two or more
creatinine measurements during hospitalization. As is
well known, AKI may have occurred but not been de-
tected on individuals receiving fewer sCr measurements.
While REGARDS measured baseline sCr on all individ-
uals, from our practical experience there can be consid-
erable drift in sCr values over time, hence making
characterization of the true baseline uncertain.
While the prevalence of comorbidities such as hyper-
tension, diabetes and hyperlipidemia seem high in this
study, they are in fact similar to the figures observed
among sepsis individuals in the larger REGARDS cohort.
Because we relied on participant reports of hospitaliza-
tions, recall or reporting biases may have resulted in
under-identification of sepsis events. However, our ap-
proach utilized prospective, systematic, dual review of
hospital records using consensus definitions. While we
did not examine more advanced sepsis levels such as se-
vere sepsis and septic shock, our study is relevant to
these more advanced stages because it identifies individ-
uals at the earliest stages of disease. We also did not
study the hospital course of sepsis or repeat sepsis
events. Due to the limited available sample size, we did not
examine other potential confounders such as medication use.Conclusions
In this pilot analysis, elevated baseline E-selectin and
ACR were associated with future episodes of AKI after
sepsis. Inflammatory and endothelial cell activation bio-
markers may play a role in the prediction of AKI risk.Methods
Study design
The Institutional Review Board of the University of
Alabama at Birmingham approved the study. We used
data from Reasons for Geographic and Racial Disparities
in Stroke (REGARDS), a population-based longitudinal
cohort. We previously performed a nested analysis using a
Table 4 Associations between baseline biomarkers and












<1.62 mg/dL Ref Ref 0.73
1.62-3.31 1.18 (0.44-3.07) 0.95 (0.34-2.60)
3.31-7.68 1.35 (0.53-3.48) 1.21 (0.45-3.24)
>7.68 0.78 (0.28-2.17) 0.74 (0.25-2.13)
TNF-α
<4.26 pg/mL Ref Ref 0.23
4.26-5.71 0.82 (0.28-2.45) 0.74 (0.24-2.26)
5.71-8.09 1.13 (0.40-3.18) 0.95 (0.32-2.79)
>8.09 2.73 (1.06-7.06) 1.68 (0.60-4.71)
IL-6
<2.41 pg/mL Ref Ref 0.50
2.41-3.56 1.84 (0.66-5.11) 1.60 (0.55-4.65)
3.56-5.92 1.35 (0.46-3.93) 1.11 (0.36-3.40)
>5.92 2.20 (0.80-6.07) 1.58 (0.58-4.82)
E-selectin
<35.05 ng/mL Ref Ref 0.045
35.05-47.09 3.17 (1.04-9.63) 2.70 (0.86-8.46)
47.09-62.48 2.05 (0.64-6.56) 1.74 (0.52-5.76)
>62.48 3.68 (1.22-11.12) 4.01 (1.27-12.69)
VCAM
<1011.85 ng/mL Ref Ref 0.73
1011.85-1172.06 1.16 (0.43-3.14) 1.31 (0.46-3.77)
1172.06-1352.13 1.05 (0.38-2.89) 0.83 (0.29-2.40)
>1352.13 1.55 (0.60-3.99) 1.29 (0.46-3.58)
ICAM
≤122.38 ng/mL Ref Ref 0.97
122.39 = 150-.76 0.55 (0.21-1.49) 0.62 (0.22-1.73)
150.77-192.26 0.72 (0.28-1.85) 0.70 (0.26-1.89)
>192.26 0.85 (0.34-2.15) 0.96 (0.37-2.54)
ACR
<30 mg/g Ref Ref <0.001
30–300 2.60 (1.14-5.96) 2.13 (0.90-5.02)
>300 12.73 (4.19-38.66) 9.70 (2.81-33.52)
Multivariable model adjusted for history of hypertension and estimated
glomerular filtration rate (eGFR). Test of trend applied to adjusted model.
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(Wang et al. 2013b).
The REGARDS cohort
REGARDS is a national community-based cohort that
includes 30,239 Black and White adults, age ≥ 45 yearsold from all regions of the continental United States.
The cohort was designed to gather data and identify risk
factors for increased incidence of stroke mortality in
Blacks and southerners (Howard et al. 2005). The
demographic composition of the cohort is: 41% African
Americans, 59% Whites, 45% men and 55% women,
and 69% individuals over 60 years old. REGARDS enrolled
patients from 2003–2007, conducting home visits and
utilizing structured interviews to gather baseline informa-
tion about participants.
Baseline data obtained for each participant included
physical characteristics (height, weight), physiology (blood
pressure, pulse, electrocardiogram), diet, family history,
psychosocial factors and prior residences, as well as bio-
logical specimens (blood, urine, etc.). The study contacted
each participant on a semi-annual basis to determine the
date, location and reason for all emergency department
visits and hospitalizations during the prior 6 months.
Upon a participant’s death, the study interviewed proxies
to ascertain the circumstances surrounding the death.
Selection of subjects
We identified all hospitalizations for a serious infection
during February 5, 2003 – October 14, 2011. We defined
serious infection hospitalization based upon taxonomies
by Angus, et al (Angus et al. 2001). Two trained abstrac-
tors independently reviewed medical records relevant to
the infection event, confirming 1) the presence of ser-
ious infection on hospital presentation, and 2) that the
infection was a primary reason for hospitalization. The
abstractors also collected clinical and laboratory infor-
mation for the first 28-hours of hospitalization. The
abstractors resolved all data discordances by consensus
review. We provided additional physician-level adjudi-
cation as needed. Based upon a review of 1,349 hospital
records, inter-rater agreement were strong for the
presence of serious infection (kappa = 0.92) and sepsis
(kappa = 0.90).
Consistent with international consensus criteria, we
defined sepsis cases as hospitalizations for serious in-
fection with two or more systemic inflammatory re-
sponse syndrome (SIRS) criteria. SIRS criteria included
body temperature > 38°C (100.4°F) or < 36°C (96.8°F),
heart rate > 90 beats per minute, respiratory rate > 20
breaths per minute or arterial carbon dioxide tension
(PaCO2) < 32 mm Hg, and abnormal white blood cell
count (>12,000/μL or < 4,000/μL or >10% immature
band forms) (Cannell et al. 2006). We did not include
end organ dysfunction in the definition of sepsis. We did
not include sepsis that developed later in hospitalization.
Outcomes – definition of acute kidney injury
A range of approaches exist for defining AKI, including
the Risk-Injury-Failure-Loss-End Stage Renal Disease
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ease Improving Global Outcomes (AKIN/KDIGO) cri-
teria (Naranbat et al. 2009). More recently, we have
proposed an AKI staging system based purely upon ab-
solute changes in sCr (Wang et al. 2013a). Consistent
with these consensus criteria, we defined AKI as a sCr
increase ≥0.3 mg/dL from the first sCr value during
hospitalization, or the initiation of hemodialysis. We did
not constrain the sCr rise to a 48 hour window, as in the
RIFLE and AKIN/KDIGO criteria. We included only
subjects with at least two serum creatinine measure-
ments during hospitalization. We excluded patients with
prior dialysis or kidney transplantation. Trained abstrac-
tors conducted a detailed chart review to identify all sCr
measurements during hospitalization as well as the need
for dialysis.
Selection and determination of biomarkers
Because of the pilot nature of this study, we focused on
markers of inflammation and endothelial cell activation
with biologically plausible connections to sepsis and AKI
pathophysiology. Additional considerations included the
sample volume requirement, and the availability and ac-
curacy of serum assays after long-term storage. Our final
selection of biomarkers included baseline interleukin-6
(IL-6), tumor necrosis factor (TNF-α), soluble endothe-
lium selectin (E-Selectin – also known as endothelial-
leukocyte adhesion molecule 1 (ELAM)), inter-cellular
adhesion molecule-1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1), and urinary Albumin-to-creatinine
ratio (ACR). The REGARDS study also measured high-
sensitivity C-Reactive Protein (hsCRP) on all individuals.
Trained personnel obtained all biomarker samples at
the time of the participant’s enrollment in to the
REGARDS cohort. The study collected blood samples
from all REGARDS participants at participants’ homes
following a 10–12 hour fast. Study personnel centrifuged
and separated serum from plasma within 2 hours of col-
lection (mean 97 minutes, SD 127 minutes). Overnight
shipping of samples on ice to the central laboratory was
achieved for 95% of the cohort. On arrival at the central
laboratory, the samples were centrifuged at 30,000 g and
4°C, and either analyzed or stored at −80°C.
Commercial biomarker kits used in the study included
HS ELISA kit (for IL-6 - R&D Systems, Minneapolis,
Minnesota), Millipore Singleplex system (for TNF-α -
Millipore, Billerica, Massachusetts, USA) and Millipore
multiplex assays (for E-Selectin, ICAM-1 and VCAM-1 -
Cardiovascular Panel 1, Millipore, Billerica, Massachusetts,
USA). hsCRP was determined in batches by particle-
enhanced immunonephelometry using the BNII nephel-
ometer (N High-sensitivity CRP; Dade Behring, Deerfield,
Illinois) with interassay CVs of 2.1%–5.7%. Urinary albu-
min and creatinine were measured using the BN ProSpecNephelometer (Dade Behring, Deerfield, Illinois). The la-
boratories performed all assays in duplicate, using the
average value in the analysis.
All analyses were conducted by The Laboratory for
Clinical Biochemistry Research, University of Vermont,
Burlington, Vermont, and the Department of Laboratory
Medicine and Pathology University of Minnesota,
Minneapolis, Minnesota.
Covariates
Covariates included demographics (age, sex, race, educa-
tion, income), health behaviors (tobacco and alcohol use)
and chronic medical conditions (hypertension, coronary
heart disease, diabetes, dyslipidemia). Racial categories in-
clude white and black; REGARDS did not recruit subjects
from other racial groups. Education categories included
less than high school, high school graduate, some college,
and college graduate. Income levels included < $20,000/
year, $20,000-34,000/year, $35,000-74,000/year, and ≥75,000/
year. We also included a category for instances where the
participant declined to provide income information.
We defined tobacco use as current, past and never.
We defined alcohol use according to the National Insti-
tute on Alcohol Abuse and Alcoholism classification:
i.e., moderate (1 drink per day for women or 2 drinks
per day for men) and heavy alcohol use (>1 drink per
day for women and >2 drinks per day for men).
We defined hypertension as baseline systolic blood
pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm
Hg, or current use of antihypertensive agents. Heart
disease included self-reported history of myocardial in-
farction, coronary artery bypass grafting, or cardiac
angioplasty or stenting, or baseline electrocardiographic
evidence of myocardial infarction. Diabetes consisted of
fasting glucose ≥126 mg/dL, non-fasting glucose ≥200 mg/dL,
or the use of insulin or oral hypoglycemic agents. Dyslipid-
emia included self-reported high cholesterol or ongoing
use of lipid lowering medications. We calculated each in-
dividual’s estimated glomerular filtration rate (eGFR)
based upon sCr measured upon enrollment in REGARDS
(Levey et al. 1999).
Data analysis
We limited the analysis to sepsis cases only. We excluded
individuals with a history of kidney transplant or end stage
renal disease, or who received less than two sCr measure-
ments during hospitalization. We compared subject char-
acteristics between those who did and did not develop
AKI during hospitalization, using the chi-square test for
categorical variables and the Wilcoxon Rank-Sum test for
continuous variables. Using logistic regression, we evalu-
ated the associations between AKI and quartiles of each
biomarker. We also conducted a test of linear trend be-
tween the quartiles of each biomarker (Szklo 2014). ACR
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nomenclature for staging chronic kidney disease. For mul-
tivariable adjustment, we included participant characteris-
tics found to be statistically significant on univariable
analysis. We conducted all analyses using Stata Version
12.1 (Stata Corp, College Station, Texas, USA).
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